268 related articles for article (PubMed ID: 28476832)
1. Prescription Patterns of Sorafenib and Outcomes of Patients with Advanced Hepatocellular Carcinoma: A National Population Study.
Lu LC; Chen PJ; Yeh YC; Hsu CH; Chen HM; Lai MS; Shao YY; Cheng AL
Anticancer Res; 2017 May; 37(5):2593-2599. PubMed ID: 28476832
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
[TBL] [Abstract][Full Text] [Related]
3. Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria.
Cho Y; Lee JH; Lee DH; Cho EJ; Yu SJ; Yi NJ; Lee KW; Kim YJ; Yoon JH; Suh KS
Oncotarget; 2017 Jul; 8(29):47555-47564. PubMed ID: 28548930
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions.
Lee SH; Song IH; Noh R; Kang HY; Kim SB; Ko SY; Lee ES; Kim SH; Lee BS; Kim AN; Chae HB; Kim HS; Lee TH; Kang YW; Lee JD; Lee HY
BMC Cancer; 2015 Apr; 15():236. PubMed ID: 25885683
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study.
Nakano M; Tanaka M; Kuromatsu R; Nagamatsu H; Tajiri N; Satani M; Niizeki T; Aino H; Okamura S; Iwamoto H; Shimose S; Shirono T; Koga H; Torimura T;
Cancer Med; 2015 Dec; 4(12):1836-43. PubMed ID: 26471348
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib.
Lim S; Han J; Kim GM; Han KH; Choi HJ
J Gastroenterol Hepatol; 2015 Jun; 30(6):1024-31. PubMed ID: 25611175
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problem.
Ziogas DC; Papadatos-Pastos D; Thillai K; Korantzis I; Chowdhury R; Suddle A; O'Grady J; Al-Khadimi G; Allen N; Heaton N; Ross PJ; Sarker D
Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):48-55. PubMed ID: 27623000
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy.
Estfan B; Byrne M; Kim R
Am J Clin Oncol; 2013 Aug; 36(4):319-24. PubMed ID: 22547010
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma.
Sanoff HK; Chang Y; Lund JL; O'Neil BH; Dusetzina SB
Oncologist; 2016 Sep; 21(9):1113-20. PubMed ID: 27185615
[TBL] [Abstract][Full Text] [Related]
10. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial.
Cainap C; Qin S; Huang WT; Chung IJ; Pan H; Cheng Y; Kudo M; Kang YK; Chen PJ; Toh HC; Gorbunova V; Eskens FA; Qian J; McKee MD; Ricker JL; Carlson DM; El-Nowiem S
J Clin Oncol; 2015 Jan; 33(2):172-9. PubMed ID: 25488963
[TBL] [Abstract][Full Text] [Related]
11. Hand-Foot Syndrome and Post-Progression Treatment Are the Good Predictors of Better Survival in Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Study.
Ogawa C; Morita M; Omura A; Noda T; Kubo A; Matsunaka T; Tamaki H; Shibatoge M; Tsutsui A; Senoh T; Nagano T; Takaguchi K; Tani J; Morishita A; Yoneyama H; Masaki T; Moriya A; Ando M; Deguchi A; Kokudo Y; Minami Y; Ueshima K; Sakurai T; Nishida N; Kudo M
Oncology; 2017; 93 Suppl 1():113-119. PubMed ID: 29258090
[TBL] [Abstract][Full Text] [Related]
12. HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma.
Lin SM; Lu SN; Chen PT; Jeng LB; Chen SC; Hu CT; Yang SS; Le Berre MA; Liu X; Mitchell DY; Prins K; Grevel J; Peña CA; Meinhardt G
Hepatol Int; 2017 Mar; 11(2):199-208. PubMed ID: 27909950
[TBL] [Abstract][Full Text] [Related]
13. Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale.
Casadei Gardini A; Faloppi L; De Matteis S; Foschi FG; Silvestris N; Tovoli F; Palmieri V; Marisi G; Brunetti O; Vespasiani-Gentilucci U; Perrone G; Valgiusti M; Granato AM; Ercolani G; Negrini G; Tamburini E; Aprile G; Passardi A; Santini D; Cascinu S; Frassineti GL; Scartozzi M
Eur J Cancer; 2017 Nov; 86():106-114. PubMed ID: 28985579
[TBL] [Abstract][Full Text] [Related]
14. Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma.
Kim HY; Park JW; Joo J; Kim H; Woo SM; Lee WJ; Kim CM
J Gastroenterol Hepatol; 2013 Nov; 28(11):1756-61. PubMed ID: 23800278
[TBL] [Abstract][Full Text] [Related]
15. In a 'real-world', clinic-based community setting, sorafenib dose of 400 mg/day is as effective as standard dose of 800 mg/day in patients with advanced hepatocellular carcimona, with better tolerance and similar survival.
Shingina A; Hashim AM; Haque M; Suen M; Yoshida EM; Gill S; Donnellan F; Weiss AA
Can J Gastroenterol; 2013 Jul; 27(7):393-6. PubMed ID: 23862169
[TBL] [Abstract][Full Text] [Related]
16. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
[TBL] [Abstract][Full Text] [Related]
17. An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma.
Peng S; Zhao Y; Xu F; Jia C; Xu Y; Dai C
PLoS One; 2014; 9(12):e112530. PubMed ID: 25460347
[TBL] [Abstract][Full Text] [Related]
18. Advanced hepatocellular carcinoma: A regional cancer center experience of 48 cases.
Lokesh KN; Chaudhuri T; Lakshmaiah KC; Babu KG; Dasappa L; Jacob LA; Suresh Babu MC; Rudresha AH; Rajeev LK
Indian J Cancer; 2017; 54(3):526-529. PubMed ID: 29798951
[TBL] [Abstract][Full Text] [Related]
19. Ginkgo biloba extract in combination with sorafenib is clinically safe and tolerable in advanced hepatocellular carcinoma patients.
Cai Z; Wang C; Liu P; Shen P; Han Y; Liu N
Phytomedicine; 2016 Nov; 23(12):1295-1300. PubMed ID: 27765348
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib prescribed by gastroenterologists and hepatologists for hepatocellular carcinoma: A retrospective, multi-institutional cohort study.
Kaplan DE; Mehta R; D'Addeo K; Valderrama A; Taddei TH;
Medicine (Baltimore); 2018 Jan; 97(4):e9757. PubMed ID: 29369224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
